DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/nhwspl/ets6103_major) has announced the addition of the "ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering.
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.
ETS6103 is being developed by e-Therapeutics for the treatment of MDD in patients who have not responded adequately to first-line therapy with an SSRI. ETS6103 is a controlled-release formulation of tramadol (e-Therapeutics, press release, October 31, 2013). Tramadol is a centrally acting synthetic analgesic compound, which is indicated for the treatment of moderate-to-severe pain.
- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on ETS6103 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for ETS6103 for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.
Key Topics Covered:
1 Table of Contents
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Unmet Needs and Opportunities
7 Pipeline Assessment
For more information visit http://www.researchandmarkets.com/research/nhwspl/ets6103_major